---
title: "enGene names Michael Heffernan board chairman as Richard Glickman steps down"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292902162.md"
description: "enGene Therapeutics appointed Michael Heffernan as board chairman, succeeding Richard Glickman who stepped down after over 14 years. Heffernan, who joined the board in July 2025 and previously founded Collegium Pharmaceutical, leads this transition ahead of planned pre-BLA FDA meetings and potential BLA submission in late 2026."
datetime: "2026-07-16T12:03:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292902162.md)
  - [en](https://longbridge.com/en/news/292902162.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292902162.md)
generator: "portal-rs"
---

# enGene names Michael Heffernan board chairman as Richard Glickman steps down

-   enGene named Michael Heffernan chairman, replacing Dr. Richard Glickman, who is stepping down after more than 14 years in the role. \* Heffernan joined the board in July 2025; he founded Collegium Pharmaceutical, serving as president, CEO, chairman. \* Board shift aligns with planned pre-BLA FDA meeting in 2H 2026, targeted BLA start in 2H 2026, potential 2027 approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607160800BIZWIRE\_USPR\_\_\_\_\_20260716\_BW174001) on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ENGN.US](https://longbridge.com/en/quote/ENGN.US.md)
- [COLL.US](https://longbridge.com/en/quote/COLL.US.md)
- [ENGNW.US](https://longbridge.com/en/quote/ENGNW.US.md)

## Related News & Research

- [Spruce Biosciences targets Q4 2026 BLA filing for TA-ERT in Sanfilippo syndrome type B after FDA meetings](https://longbridge.com/en/news/296784399.md)
- [Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA | CAPR Stock News](https://longbridge.com/en/news/296796113.md)
- [Vanda says EU grants orphan drug status to imsidolimab for generalized pustular psoriasis](https://longbridge.com/en/news/296776870.md)
- [Humacyte says Phase 3 V012 trial shows ATEV extends catheter-free dialysis time in women](https://longbridge.com/en/news/296784335.md)
- [West Family Investments Inc. Buys Shares of 7,697 Mid-America Apartment Communities, Inc. $MAA](https://longbridge.com/en/news/296470077.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**